{"mainPropery":{"diseaseId":7108,"diseaseName":"Multiple myeloma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7108/multiple-myeloma","synonyms":["Plasma cell myeloma","Kahler disease","Myelomatosis","Plasma cell dyscrasia","Myeloma - multiple"],"synonyms-with-source":[{"name":"Plasma cell myeloma"},{"name":"Kahler disease"},{"name":"Myelomatosis"},{"name":"Plasma cell dyscrasia"},{"name":"Myeloma - multiple"}],"identifiers":[{"identifierType":"OMIM","identifierId":"254500"},{"identifierType":"ORPHANET","identifierId":"29073"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":157,"resourceName":"Cancer Hope Network","abbreviation":"","address1":"2 North Road, Suite A","address2":"","address3":"","address4":"","address5":"","city":"Chester","state":"NJ","zip":"07930","country":"United States","phone":"+1-908-879-4039","tty":"","tollFree":"1-877-467-3638 (1-877-HOPENET)","fax":"+1-908-879-6518","email":"info@cancerhopenetwork.org/","url":"https://www.cancerhopenetwork.org/","freeText":""},{"resourceID":312,"resourceName":"CancerCare","address1":"275 Seventh Ave, Floor 22","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10001 ","country":"United States","phone":"","tty":"","tollFree":"800-813-HOPE","fax":"212-712-8495 ","email":"info@cancercare.org","url":"http://www.cancercare.org/"},{"resourceID":469,"resourceName":"The National Coalition for Cancer Survivorship","address1":"1010 Wayne Avenue","address2":"Suite 770","address3":"","address4":"","address5":"","city":"Silver Spring","state":"MD","zip":"20910 ","country":"United States","phone":"301-650-9127 ","tty":"","tollFree":"888-650-9127","fax":"301-565-9670 ","email":"info@canceradvocacy.org","url":"http://www.canceradvocacy.org"},{"resourceID":607,"resourceName":"International Myeloma Foundation","abbreviation":"","address1":"12650 Riverside Drive, Suite 206","address2":"","address3":"","address4":"","address5":"","city":"North Hollywood","state":"CA","zip":"91607-3421","country":"United States","phone":"818-487-7455","tty":"","tollFree":"800-452-2873","fax":"","email":"TheIMF@myeloma.org","url":"http://myeloma.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/254500' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=multiple%20myeloma%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Multiple myeloma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Multiple+myeloma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Multiple myeloma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='https://ghr.nlm.nih.gov/condition/multiple-myeloma' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Multiple myeloma. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":102,"resourceId":120,"resourceName":"American Cancer Society","descriptionText":"The <a href='http://www.cancer.org/cancer/multiplemyeloma/' target='_blank'>American Cancer Society</a> provides information on Multiple myeloma. Please click on the link to access this resource.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":336,"resourceId":1154,"resourceName":"RareConnect","descriptionText":"<div style=\"margin-top: 0px; margin-bottom: 0px;\"><a href='https://www.rareconnect.org/en/community/multiple-myeloma' target='_blank'>RareConnect</a> has an online community for patients&nbsp;and families with this condition so they can connect with others and share&nbsp;their experiences living with a rare disease.&nbsp;The project is a joint collaboration between EURORDIS (European Rare Disease Organisation) and NORD (National Organization for Rare Disorders).</div>","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":775,"resourceId":1860,"resourceName":"Mayo Clinic","descriptionText":"<a href='http://www.mayoclinic.org/diseases-conditions/multiple-myeloma/basics/definition/con-20026607' target='_blank'>Mayo Clinic</a> has an information page on Multiple myeloma.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0026764' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/566/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='https://www.nlm.nih.gov/medlineplus/ency/article/000583.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/204369-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=29073' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/types/myeloma' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='http://www.merckmanuals.com/home/sec14/ch175/ch175c.html?qt=ultiple%20myeloma&alt=sh' target='_blank'>Merck Manuals Online Medical Library</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:254500' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/multiple-myeloma' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2170,"resourceId":3379,"resourceName":"Journal articles - Multiple myeloma","descriptionText":"Sonneveld P et al.,  <a target=\"_blank\" href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920674/\">Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group</a>. <em>Blood</em>. 2016 Jun 16;127(24):2955-62.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"}],"overviewQuestion":{"questionId":4371,"questionText":"What is multiple myeloma?","answerText":"<strong>Multiple myeloma</strong> is a form of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001289.htm\" target=\"_blank\">cancer</a> that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs.[10896][3783][10897] The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of <a href=\"https://rarediseases.info.nih.gov/gard/7034/monoclonal-gammopathy-of-undetermined-significance/resources/1\" target=\"_blank\">monoclonal gammopathy of undetermined significance (MGUS</a>).[10896][3783][10895] Treatment varies based on many factors, but may include one or more of the following interventions: <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">chemotherapy</a>, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45658\" target=\"_blank\">corticosteroid</a> medications, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742\" target=\"_blank\">targeted therapy</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">stem cell transplant</a>, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45617\" target=\"_blank\">biological therapy</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a>, surgery and/or <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45942\" target=\"_blank\">watchful waiting</a>.[10896][3783][10897]","dateModified":"2016-03-12T00:00:00"},"basicQuestions":[{"questionId":4818,"questionText":"What are the signs and symptoms of multiple myeloma?","answerText":"In some cases, multiple myeloma is not associated with any signs and symptoms. When present, the most common symptom is <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000560.htm\" target=\"_blank\">anemia</a> (low red blood cell count), which can be associated with fatigue, shortness of breath, and dizziness. Other features of the condition may include:[3783][3782][10879]\r\n<ul>\r\n    <li>Bone pain</li>\r\n    <li>Nausea</li>\r\n    <li>Constipation</li>\r\n    <li>Loss of appetite</li>\r\n    <li>Frequent infections</li>\r\n    <li>Weight loss</li>\r\n    <li>Excessive thirst</li>\r\n    <li>Weakness and/or numbness in the arms and legs</li>\r\n    <li>Confusion</li>\r\n    <li>Abnormal bleeding</li>\r\n    <li>Weak bones that may break easily</li>\r\n    <li>Difficulty breathing</li>\r\n</ul>","dateModified":"2016-03-09T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":3782,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2015","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10879,"authors":"S Vincent Rajkumar, MD","articleTitle":"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma","bookWebsiteJournalTitle":"UpToDate","date":"January 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4819,"questionText":"What causes multiple myeloma?","answerText":"Although the exact underlying cause of multiple myeloma is poorly understood, the specific symptoms of the condition result from abnormal and excessive growth of plasma cells in the bone marrow. Plasma cells help the body fight infection by producing proteins called <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002223.htm\" target=\"_blank\">antibodies</a>. In people with multiple myeloma, excess plasma cells form tumors in the bone, causing bones to become weak and easily broken. The abnormal growth of plasma cells also makes it more difficult for the bone marrow to make healthy blood cells and platelets. The plasma cells produced in multiple myeloma produce abnormal antibodies that the immune system is unable to use. These abnormal antibodies build up in the body and cause a variety of problems.[3783][10895][3782] <br />\r\n<br />\r\nFactors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of <a href=\"https://rarediseases.info.nih.gov/gard/7034/monoclonal-gammopathy-of-undetermined-significance/resources/1\" target=\"_blank\">monoclonal gammopathy of undetermined significance (MGUS</a>).[10896][3783][10895]","dateModified":"2016-03-10T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":3782,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2015","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10895,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Mayo Clinic","date":"December 2015","volume":"","pages":"","url":"http://www.mayoclinic.org/diseases-conditions/multiple-myeloma/basics/definition/con-20026607","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4820,"questionText":"How&nbsp;is multiple myeloma diagnosed?","answerText":"A diagnosis of multiple myeloma may be suspected based on the presence of characteristic <a href=\"https://rarediseases.info.nih.gov/gard/7108/multiple-myeloma/resources/9\" target=\"_blank\">signs and symptoms</a>. Additional testing can then be ordered to confirm the diagnosis. This may include:[10896][10897][3783]<br />\r\n<ul>\r\n    <li>Specialized blood tests including <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45725\" target=\"_blank\">immunoglobulin</a> studies, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45107\" target=\"_blank\">complete blood count with differential</a>, and <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=304685\" target=\"_blank\">blood chemistry studies</a></li>\r\n    <li>Urine tests such as immunoglobulin studies and a twenty-four-hour urine test</li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=669655\" target=\"_blank\">Bone marrow aspiration and biopsy</a></li>\r\n    <li>Imaging studies such as an <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003337.htm\" target=\"_blank\">X-ray</a> of the bones (skeletal bone survey), <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003335.htm\" target=\"_blank\">MRI</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003330.htm\" target=\"_blank\">CT scan</a>, and/or <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003827.htm\" target=\"_blank\">PET scan</a></li>\r\n</ul>\r\nThe <a href=\"http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-testing\" target=\"_blank\">American Cancer Society</a> offers more information regarding the diagnosis of multiple myeloma, including a summary of the many tests that may be recommended. Please click on the link to access this resource. <br />\r\n<br />\r\nSome affected people may have no suspicious signs or symptoms of multiple myeloma, especially in the early stages of the condition. In these cases, multiple myeloma is sometimes diagnosed by chance when a blood test or urine test is ordered to investigate another condition.[10897]","dateModified":"2016-03-10T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10897,"authors":"","articleTitle":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"October 2015","volume":"","pages":"","url":"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4821,"questionText":"How might&nbsp;multiple myeloma&nbsp;be treated?","answerText":"The treatment of multiple myeloma varies based on many factors including the age and general health of the affected person; the associated signs and symptoms; and the severity of the condition. In general, one or more of the following interventions may be used to treat multiple myeloma:[10896][3783][10897]<br />\r\n<ul>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">Chemotherapy</a> </li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45658\" target=\"_blank\">Corticosteroid</a> medications</li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742\" target=\"_blank\">Targeted therapy</a></li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">Stem cell transplant</a></li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45617\" target=\"_blank\">Biological therapy</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">Radiation therapy</a> </li>\r\n    <li>Surgery</li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45942\" target=\"_blank\">Watchful waiting</a></li>\r\n</ul>\r\nThe <a href=\"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/_46\" target=\"_blank\">National Cancer Institute</a> offers information regarding the management of multiple myeloma, including more specific information regarding the treatments outlined above. Please click on the link to access this resource.","dateModified":"2016-03-10T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10897,"authors":"","articleTitle":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"October 2015","volume":"","pages":"","url":"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4822,"questionText":"What is the&nbsp;long-term outlook&nbsp;for people with multiple myeloma?","answerText":"The long-term outlook (prognosis) for people with multiple myeloma can be difficult to predict as some cases progress rapidly despite treatment, while others remain stable without therapy for a number of years. However, some general patterns have been observed. For example, prognosis appears to vary based on the affected person's age and the stage of the condition at the time of diagnosis. In general, survival is higher in younger people and lower in&nbsp;the elderly. Other factors that can be associated with a poor prognosis include a high tumor burden and kidney damage.[10896][3782][10900]<br />\r\n<br />\r\nInfections are an important cause of early death among people with multiple myeloma. In fact, studies show that the risk of both bacterial infections and viral infections is approximately&nbsp;seven times higher in people affected by the condition.[10896] <br />","dateModified":"2016-03-11T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":3782,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2015","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10900,"authors":"S Vincent Rajkumar, MD","articleTitle":"Staging and prognostic studies in multiple myeloma","bookWebsiteJournalTitle":"UpToDate","date":"January 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":31348,"abbreviatedInquiry":"My daughter has just been diagnosed with multiple myeloma.&nbsp;Is it survivable? Please send me all the information you have.","caseQuestions":[{"questionId":4371,"questionText":"What is multiple myeloma?","answerText":"<strong>Multiple myeloma</strong> is a form of <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001289.htm\" target=\"_blank\">cancer</a> that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs.[10896][3783][10897] The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of <a href=\"https://rarediseases.info.nih.gov/gard/7034/monoclonal-gammopathy-of-undetermined-significance/resources/1\" target=\"_blank\">monoclonal gammopathy of undetermined significance (MGUS</a>).[10896][3783][10895] Treatment varies based on many factors, but may include one or more of the following interventions: <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">chemotherapy</a>, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45658\" target=\"_blank\">corticosteroid</a> medications, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742\" target=\"_blank\">targeted therapy</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">stem cell transplant</a>, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45617\" target=\"_blank\">biological therapy</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">radiation therapy</a>, surgery and/or <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45942\" target=\"_blank\">watchful waiting</a>.[10896][3783][10897]","dateModified":"2016-03-12T00:00:00","references":[{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10895,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Mayo Clinic","date":"December 2015","volume":"","pages":"","url":"http://www.mayoclinic.org/diseases-conditions/multiple-myeloma/basics/definition/con-20026607","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10897,"authors":"","articleTitle":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"October 2015","volume":"","pages":"","url":"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4818,"questionText":"What are the signs and symptoms of multiple myeloma?","answerText":"In some cases, multiple myeloma is not associated with any signs and symptoms. When present, the most common symptom is <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000560.htm\" target=\"_blank\">anemia</a> (low red blood cell count), which can be associated with fatigue, shortness of breath, and dizziness. Other features of the condition may include:[3783][3782][10879]\r\n<ul>\r\n    <li>Bone pain</li>\r\n    <li>Nausea</li>\r\n    <li>Constipation</li>\r\n    <li>Loss of appetite</li>\r\n    <li>Frequent infections</li>\r\n    <li>Weight loss</li>\r\n    <li>Excessive thirst</li>\r\n    <li>Weakness and/or numbness in the arms and legs</li>\r\n    <li>Confusion</li>\r\n    <li>Abnormal bleeding</li>\r\n    <li>Weak bones that may break easily</li>\r\n    <li>Difficulty breathing</li>\r\n</ul>","dateModified":"2016-03-09T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":3782,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2015","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10879,"authors":"S Vincent Rajkumar, MD","articleTitle":"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma","bookWebsiteJournalTitle":"UpToDate","date":"January 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4819,"questionText":"What causes multiple myeloma?","answerText":"Although the exact underlying cause of multiple myeloma is poorly understood, the specific symptoms of the condition result from abnormal and excessive growth of plasma cells in the bone marrow. Plasma cells help the body fight infection by producing proteins called <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002223.htm\" target=\"_blank\">antibodies</a>. In people with multiple myeloma, excess plasma cells form tumors in the bone, causing bones to become weak and easily broken. The abnormal growth of plasma cells also makes it more difficult for the bone marrow to make healthy blood cells and platelets. The plasma cells produced in multiple myeloma produce abnormal antibodies that the immune system is unable to use. These abnormal antibodies build up in the body and cause a variety of problems.[3783][10895][3782] <br />\r\n<br />\r\nFactors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of <a href=\"https://rarediseases.info.nih.gov/gard/7034/monoclonal-gammopathy-of-undetermined-significance/resources/1\" target=\"_blank\">monoclonal gammopathy of undetermined significance (MGUS</a>).[10896][3783][10895]","dateModified":"2016-03-10T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":3782,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2015","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10895,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Mayo Clinic","date":"December 2015","volume":"","pages":"","url":"http://www.mayoclinic.org/diseases-conditions/multiple-myeloma/basics/definition/con-20026607","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4820,"questionText":"How&nbsp;is multiple myeloma diagnosed?","answerText":"A diagnosis of multiple myeloma may be suspected based on the presence of characteristic <a href=\"https://rarediseases.info.nih.gov/gard/7108/multiple-myeloma/resources/9\" target=\"_blank\">signs and symptoms</a>. Additional testing can then be ordered to confirm the diagnosis. This may include:[10896][10897][3783]<br />\r\n<ul>\r\n    <li>Specialized blood tests including <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45725\" target=\"_blank\">immunoglobulin</a> studies, <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45107\" target=\"_blank\">complete blood count with differential</a>, and <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=304685\" target=\"_blank\">blood chemistry studies</a></li>\r\n    <li>Urine tests such as immunoglobulin studies and a twenty-four-hour urine test</li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=669655\" target=\"_blank\">Bone marrow aspiration and biopsy</a></li>\r\n    <li>Imaging studies such as an <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003337.htm\" target=\"_blank\">X-ray</a> of the bones (skeletal bone survey), <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003335.htm\" target=\"_blank\">MRI</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003330.htm\" target=\"_blank\">CT scan</a>, and/or <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003827.htm\" target=\"_blank\">PET scan</a></li>\r\n</ul>\r\nThe <a href=\"http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-testing\" target=\"_blank\">American Cancer Society</a> offers more information regarding the diagnosis of multiple myeloma, including a summary of the many tests that may be recommended. Please click on the link to access this resource. <br />\r\n<br />\r\nSome affected people may have no suspicious signs or symptoms of multiple myeloma, especially in the early stages of the condition. In these cases, multiple myeloma is sometimes diagnosed by chance when a blood test or urine test is ordered to investigate another condition.[10897]","dateModified":"2016-03-10T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10897,"authors":"","articleTitle":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"October 2015","volume":"","pages":"","url":"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4821,"questionText":"How might&nbsp;multiple myeloma&nbsp;be treated?","answerText":"The treatment of multiple myeloma varies based on many factors including the age and general health of the affected person; the associated signs and symptoms; and the severity of the condition. In general, one or more of the following interventions may be used to treat multiple myeloma:[10896][3783][10897]<br />\r\n<ul>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">Chemotherapy</a> </li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45658\" target=\"_blank\">Corticosteroid</a> medications</li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742\" target=\"_blank\">Targeted therapy</a></li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">Stem cell transplant</a></li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45617\" target=\"_blank\">Biological therapy</a></li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/001918.htm\" target=\"_blank\">Radiation therapy</a> </li>\r\n    <li>Surgery</li>\r\n    <li><a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45942\" target=\"_blank\">Watchful waiting</a></li>\r\n</ul>\r\nThe <a href=\"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq#section/_46\" target=\"_blank\">National Cancer Institute</a> offers information regarding the management of multiple myeloma, including more specific information regarding the treatments outlined above. Please click on the link to access this resource.","dateModified":"2016-03-10T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":3783,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"American Cancer Society","date":"January 2016","volume":"","pages":"","url":"http://www.cancer.org/Cancer/MultipleMyeloma/DetailedGuide/index","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10897,"authors":"","articleTitle":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment","bookWebsiteJournalTitle":"National Cancer Institute","date":"October 2015","volume":"","pages":"","url":"http://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4822,"questionText":"What is the&nbsp;long-term outlook&nbsp;for people with multiple myeloma?","answerText":"The long-term outlook (prognosis) for people with multiple myeloma can be difficult to predict as some cases progress rapidly despite treatment, while others remain stable without therapy for a number of years. However, some general patterns have been observed. For example, prognosis appears to vary based on the affected person's age and the stage of the condition at the time of diagnosis. In general, survival is higher in younger people and lower in&nbsp;the elderly. Other factors that can be associated with a poor prognosis include a high tumor burden and kidney damage.[10896][3782][10900]<br />\r\n<br />\r\nInfections are an important cause of early death among people with multiple myeloma. In fact, studies show that the risk of both bacterial infections and viral infections is approximately&nbsp;seven times higher in people affected by the condition.[10896] <br />","dateModified":"2016-03-11T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":3782,"authors":"","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2015","volume":"","pages":"","url":"http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10896,"authors":"Dhaval Shah, MD","articleTitle":"Multiple Myeloma","bookWebsiteJournalTitle":"Medscape Reference","date":"February 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/204369-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10900,"authors":"S Vincent Rajkumar, MD","articleTitle":"Staging and prognostic studies in multiple myeloma","bookWebsiteJournalTitle":"UpToDate","date":"January 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]}]},{"caseId":30429,"abbreviatedInquiry":"What is the current understanding of the risk for developing multiple myeloma among first degree relatives of an affected person?&nbsp;For example,&nbsp;if a parent has been diagnosed with multiple myeloma, what is the&nbsp;risk to&nbsp;a child?","caseQuestions":[{"questionId":4373,"questionText":"What is the risk to first-degree relatives of an individual who has been diagnosed with multiple myeloma?","answerText":"Multiple myeloma usually occurs <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK5191/def-item/sporadic/\" target=\"_blank\">sporadically</a> within a family and very little is known about familial and/or hereditary forms.[3327][3325] Several families have been reported with multiple cases of multiple myeloma. The existence of hereditary multiple myeloma is, therefore, suggested, but no single gene  known to cause the condition have been identified.[3327] Studies have found that a person's risk of multiple myeloma may be higher if a close relative had the disease. For example, first-degree relatives (i.e. parents, children) of people with multiple myeloma are reported to be two-to four-times more likely to develop the condition; it is presumed the risks are higher for relatives in the case of familial ;multiple myeloma (where multiple people have already been diagnosed).[3327] Multiple myeloma among married couples and \"community clusters\" of multiple myeloma have also been described, suggesting the potential importance of environmental factors, as well.[3324]","dateModified":"2016-03-11T00:00:00","references":[{"referenceId":3324,"authors":"Henry T. Lynch et al","articleTitle":"Familial Multiple Myeloma: a Family Study and Review of the Literature","bookWebsiteJournalTitle":"","date":"2001","volume":"93(19)","pages":"1479-1483","url":"http://jnci.oxfordjournals.org/content/93/19/1479.full","dateAccessed":"2011-04-20T00:00:00"},{"referenceId":3325,"authors":"Henry T. Lynch and Stephan D. Thomé","articleTitle":"Familial multiple myeloma","bookWebsiteJournalTitle":"Blood","date":"July 23, 2009","volume":"14(4)","pages":"749-750","url":"http://bloodjournal.hematologylibrary.org/content/114/4/749.long","dateAccessed":"2011-04-20T00:00:00"},{"referenceId":3327,"authors":"Gerkes EH, de Jong MM, Sijmons RH, Vellenga E","articleTitle":"Familial multiple myeloma: report on two families and discussion of screening options","bookWebsiteJournalTitle":"Hereditary Cancer in Clinical Practice","date":"June 15, 2007","volume":"5(2)","pages":"72-78","url":"http://www.ncbi.nlm.nih.gov/pubmed/19725987","dateAccessed":"2011-04-20T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":10265,"phenoTypeName":"Osteopenia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10709,"phenoTypeName":"Pathologic fracture","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":15550,"phenoTypeName":"Acute kidney injury","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15539,"phenoTypeName":"Anemia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13280,"phenoTypeName":"Bone pain","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3592,"phenoTypeName":"Decreased circulating antibody level","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10946,"phenoTypeName":"Elevated serum creatinine","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11006,"phenoTypeName":"Generalized muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13831,"phenoTypeName":"Hyperproteinemia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10934,"phenoTypeName":"Increased circulating IgG level","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10043,"phenoTypeName":"Nephropathy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6347,"phenoTypeName":"Nephrotic syndrome","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5,"phenoTypeName":"Abnormality of the bladder","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3578,"phenoTypeName":"Abnormality of vitamin B12 metabolism","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9054,"phenoTypeName":"Functional abnormality of the gastrointestinal tract","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14530,"phenoTypeName":"Hypercalcemia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10948,"phenoTypeName":"Increased circulating IgA level","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5592,"phenoTypeName":"Paresthesia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13850,"phenoTypeName":"Spinal cord compression","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10035,"phenoTypeName":"Tall stature","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4352,"phenoTypeName":"Vertebral compression fractures","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13313,"phenoTypeName":"Lymphadenopathy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13873,"phenoTypeName":"Pleural effusion","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14107,"phenoTypeName":"Amyloidosis","percentRanges":"-"},{"phenoTypeId":12123,"phenoTypeName":"Multiple myeloma","percentRanges":"-"},{"phenoTypeId":5524,"phenoTypeName":"Paraproteinemia","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":228,"genericName":"Melphalan","tradeName":"Alkeran® (injection)","tradeLink":"http://us.gsk.com/products/assets/us_alkeran_tablets.pdf","manufacturer":"","sponsor":"Glaxo Wellcome Inc.","indication":"For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Alkeran","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682220.html"},{"productId":631,"genericName":"Daratumumab","tradeName":"Darzalex","tradeLink":"https://www.darzalex.com/","manufacturer":"","sponsor":"Janssen Research & Development, LLC","indication":"May 2018 approved in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. June 2017 approved in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. November 2016 approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/darzalex","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a616002.html"},{"productId":302,"genericName":"Doxorubicin HCL liposome injection","tradeName":"Doxil® (injection)","tradeLink":"http://www.doxil.com/","manufacturer":"Centocor Ortho Biotech Inc.","sponsor":"Johnson & Johnson Pharmaceutical Research & Dev.","indication":"For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior\r\ntherapy.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?regno=023214928","medlinePlusLink":""},{"productId":744,"genericName":"Elotuzumab","tradeName":"Empliciti","tradeLink":"https://www.empliciti.com","manufacturer":"","sponsor":"Bristol-Myers Squibb Co.","indication":"November 2018, elotuzumab (Empliciti)  was approved in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. In November 2015, it was approved  in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/empliciti","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a616001.html"},{"productId":552,"genericName":"Carfilzomib","tradeName":"Kyprolis","tradeLink":"http://www.kyprolis.com/","manufacturer":"","sponsor":"Onyx Therapeutics, Inc.","indication":"Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  ","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0868540174&QV1=CARFILZOMIB","medlinePlusLink":""},{"productId":635,"genericName":"Ixazomib citrate","tradeName":"Ninlaro","tradeLink":"http://www.ninlaro.com/","manufacturer":"","sponsor":"Millennium Pharmaceuticals","indication":"Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Ixazomib","medlinePlusLink":""},{"productId":569,"genericName":"Pomalidomide","tradeName":"Pomalyst","tradeLink":"http://www.pomalyst.com/","manufacturer":"","sponsor":"Celgene Corporation","indication":"Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.","drugInformationLink":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a613030.html"},{"productId":86,"genericName":"Lenalidomide","tradeName":"Revlimid","tradeLink":"http://www.revlimid.com/","manufacturer":"","sponsor":"Celgene Corporation","indication":"For use in combination with dexamethasone for the treatment of multiple myeloma. Also, for use  for the treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT).","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/revlimid","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a608001.html"},{"productId":88,"genericName":"Thalidomide","tradeName":"Thalomid","tradeLink":"http://www.thalomid.com/","manufacturer":"","sponsor":"Celgene Corporation","indication":"Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/thalomid","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a699032.html"},{"productId":342,"genericName":"Bortezomib","tradeName":"Velcade®","tradeLink":"http://www.velcade.com/","manufacturer":"","sponsor":"Millennium Pharmaceuticals, Inc.","indication":"Treatment of multiple myeloma patients who have received at least one prior therapy.\r\n\r\nTreatment of patients with mantle cell lymphoma.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Velcade","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a693049.html"}],"EncodedName":"Multiple_myeloma"}